Florencia McAllister
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (22)
Supplementary figures and legends showing CAM effect on organ weight and blood chemistry analysis; survival study of CAM supplemented in chow diet; IHC staining of proliferation, apoptosis and angiogenesis; CAM treatment effect on lung microbiome.
Year:
2026
Drug repurposing is the process of reusing existing pharmaceuticals for novel clinical purposes, which offers advantages such as streamlined clinical trial access and reduced drug development costs. Clarithromycin (CAM), a member of the macrolide antibiotics family, is a promising candidate for repurposing in cancer therapy due to its known preclinical and clinical immunomodulatory and anticancer properties. In the current study, we investigated whether CAM could be repurposed as a preventive treatment for KRAS -mutant lung cancer, a subtype of lung adenocarcinoma that is strongly associated with heavy smoking. CCSP Cre ; LSL-Kras G12D mice at an early stage of tumor development were treated with different doses of CAM for 10 weeks. While exhibiting an excellent safety profile, CAM was able to prevent the development of premalignant and malignant lung lesions in a dose-dependent manner. In addition, CAM significantly reduced the infiltration of neutrophils/polymorphonuclear myeloid-derived suppressor cells and inhibited the mRNA expression of protumor inflammatory cytokines IL-6, TNFα, and IL-1β, as well as M2 macrophage markers Fizz1 and Arginase1 in the lung tumor microenvironment. Moreover, we investigated the effect of CAM in reshaping the intestinal and lung microbiome. Long-term CAM usage decreased intestinal microbiome diversity but, more notably, significantly increased the abundance of the probiotic genus Muribaculaceae while decreasing the abundance of Desulfovibrio , a genus associated with the promotion of various malignancies. Taken together, we conclude that CAM could provide promising cancer prevention efficacy in KRAS -mutant lung cancer due to its immunomodulatory properties on the tumor microenvironment and its regulatory effects on the microbiome.
Year:
2026
Introduction: nephron-sparing surgery (NSS) has emerged as the preferred treatment for renal tumors, aiming to balance oncological outcomes and renal function preservation. Partial nephrectomy (PN) has shown comparable cancer-specific survival rates to radical nephrectomy (RN). Notably, postoperative renal damage is associated with both ischemia time and parenchymal loss, emphasizing the importance of preserving renal function during tumor resection. The R.E.N.A.L. Nephrometry Score (RNS), has enhanced the quantification of renal tumor characteristics and improved standardization, guiding surgical decisions. This study aims to describe different hilum approaches based on RNS during laparoscopic PN and analyze their impact on surgical time, intraoperative bleeding, and functional outcomes. Methods: a retrospective analysis of 90 laparoscopic partial nephrectomy cases was conducted. Surgical time, estimated blood loss (EBL), renal hilum approach (including hilum dissection with renal artery clamping [HD&RAC], hilum dissection without renal artery clamping [HD&noRAC], and no hilum dissection with no renal artery clamping [noHD&noRAC), complication rates and RNS-guided complexity (low: RNS 9) were assessed. The choice of hilum approach and abdominal access was determined by the physician based on tumor complexity assessed using RNS. Results: surgical time varied significantly between hilum approaches, with HD&RAC being the longest (196min), followed by HD&noRAC (147min) and noHD&noRAC (130min). The mean surgical time was statistically significantly different between HD&RAC and HD&noRAC (p-value = 0.0005) and between HD&RAC and noHD&noRAC (p-value = 0.0001). Intraoperative bleeding was higher in the HD&RAC approach than the noHD&noRAC approach (p-value = 0.039). Pre- and post-surgery glomerular filtration rates did not significantly differ by hilum approach (p= 0.7255) or complexity of the renal mass (p= 0.5633). No intraoperative complications were reported. However, three patients with high RNS experienced postoperative urinary fistulas. Conclusion: the choice of renal hilum approach significantly impacts surgical time and intraoperative bleeding during laparoscopic partial nephrectomy. Using RNS to guide the approach selection allows for optimal surgical outcomes without compromising glomerular filtration rate (GFR). Further research is needed to validate these findings in larger, multicenter studies and assess long-term outcomes associated with different hilum approaches in laparoscopic PN.
Year:
2026
Dietary macronutrient composition has emerged as a key modulator of pancreatic tumorigenesis, yet the impact of lipid-rich diets, particularly ketogenic diets (KD) on the earliest stages of pancreatic cancer development remains unclear. To investigate how dietary lipids shape the initiation and progression of Kras-driven neoplasia, we examined the effects of low-fat diet (LFD), high-fat diet (HFD), and KD in the Ptf1a CreERT2 ;Kras G12V (Acinar KrasG12V ) mouse model. KD-fed mice showed the shortest survival (median 26 ± 7 days) compared with SD (87 ± 29; p = 0.02) and LFD (57 ± 27; p = 0.02), while HFD-fed mice also exhibited reduced survival relative to SD (35 ± 25; p = 0.05). KD feeding induced severe glucose intolerance and elevated circulating β-hydroxybutyrate levels. Histologically, KD-fed Acinar KrasG12V mice developed invasive, sarcomatoid-like pancreatic ductal adenocarcinoma (PDAC), while HFD-fed mice showed increased poorly differentiated PDAC; in both groups these aggressive tumors were associated with extensive fibrosis and increased stromal CD39 expression relative to tumor compartments. Proteomic analysis demonstrated activation of PI3K–Akt–mTOR and EGFR signaling in KD and HFD-fed Acinar KrasG12V mice. Serum cytokines/chemokines profiling revealed pro-inflammatory and pro-angiogenic milieu in KD-fed Acinar KrasG12V mice. Collectively, these results show that dietary lipid enrichment prior to oncogenic Kras activation may accelerate early pancreatic neoplasia and foster a microenvironment conducive to tumor progression. These findings underscore the need for careful consideration of KD use in individuals at elevated risk for pancreatic cancer.
Year:
2025
Table S6. Gene set enrichment analysis using the KEGG pathways and Gene Ontology Biological Processes databases. Pathways statistically significant activated or suppressed after twelve months exercise are displayed (BH-adjusted P-value
Year:
2025
Table S2. Number of Patients Experiencing Adverse Events by Maximum Grade consent and initiation of exercise regimen (Pre-Study) and in the exercise and usual care group. List with the number of patients experiencing adverse events. Should a patient experience any adverse event, the patient is counted only at the highest (maximum) grade experienced.
Year:
2025
Figure S5. (A) Gene Set Enrichment Analysis (GSEA) of BIOCARTA IL-6 pathway; (B) Gene set of IL-6-stimulated cell cultures; (C) Gene set in IL-6-deprived cell cultures. GSEA was performed by 1000 permutations. The maximum and minimum sizes for gene sets were 500 and 15, respectively. The y-axis represents the enrichment score (ES) and the x-axis lists the ranked genes by fold change. Vertical black lines on the x-axis represent the genes in gene sets. The green line connects points of ES and genes. ES is the maximum deviation from zero as calculated for each gene going down the ranked list and represents the degree of over-representation of a gene set at the top or the bottom of the ranked gene list. The P-value and ES are labeled at the top of the figure. The peak towards to left of the x-axis suggests a positive enrichment of the target gene set and vice versa.
Year:
2025
Table S3. Number of patients experiencing adverse events. Only those toxicities experienced while on the trial are presented in the table. Toxicities during the pre-study stage of the trial, for example, that were present before participants begin intervention were not included. Should a patient experience an adverse event more than once, the patient is only counted once at the highest grade for that adverse event.
Year:
2025
Table S1. Adverse events (AEs) experience by participants with possible or probable relation to the study intervention. Summary of the adverse events by grade, relationship, and arm. Adverse events were reported by subjects, including AEs that happened between consent and initiation of exercise regimen (Pre-Study) and in the exercise and usual care group.
Year:
2025
Figure S4. Relative change in prostaglandin metabolite levels after twelve months follow-up in usual care and exercise groups (A-C, Wilcoxon signed-rank test; ns, P>0.05; *, P ≤0.05; **, P≤0.01).
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (40)
Karen Basen-Engquist
The University of Texas MD Anderson Cancer Center
Dafna Bar-Sagi
NYU School of Medicine
Daniel A. Laheru
Johns Hopkins University School of Medicine
Kyle Poulsen
Assistant Professor
Michigan State University
Parul Agarwal
Assistant Professor
University of Pennsylvania
Holger Eltzschig
Professor and Chairman
McGovern Medical School at UTHealth
Johannes Fahrmann
Assistant Professor
The University of Texas MD Anderson Cancer Center
Erika Yanil Faraoni
The University of Texas MD Anderson Cancer Center
Nirav Thosani
Division Director/Professor
The University of Texas Health Science Center at Houston
Yisheng LI
Professor
The University of Texas MD Anderson Cancer Center
Susan C. Gilchrist
Professor
University of North Carolina at Chapel Hill
Alison Klein
Professor
-
Samir M. Hanash
The University of Texas MD Anderson Cancer Center
C. Marcelo Aldaz
Professor
The University of Texas MD Anderson Cancer Center
James P. Allison
Professor and Chair
The University of Texas MD Anderson Cancer Center
Eduardo Vilar
Assistant Professor
The University of Texas MD Anderson Cancer Center
Patrick Lynch
Professor
The University of Texas MD Anderson Cancer Center
Tingting Mills
Assistant Professor
The University of Texas Health Science Center at Houston
Zhongming Zhao
Professor and Center Director
The University of Texas Health Science Center at Houston
Jennifer A. Wargo
The University of Texas MD Anderson Cancer Center
Matthew H. G. Katz
Professor
-
yulin dai
The University of Texas Health Science Center at Houston
Ana De Jesus-Acosta
Johns Hopkins University
curtis wray
Professor
The University of Texas Health Science Center at Houston
Manoj Chelvanambi
The University of Texas MD Anderson Cancer Center
Thais Bartelli
Research Investigator
The University of Texas MD Anderson Cancer Center
Seyed Javad Moghaddam
Professor
The University of Texas MD Anderson Cancer Center
Jennifer Bailey-Lundberg
Tenured Associate Professor
The University of Texas Health Science Center at Houston
Ernest Hawk
The University of Texas MD Anderson Cancer Center
Michael P. Kim
Associate Professor
The University of Texas MD Anderson Cancer Center
Alexander Lazar
Professor
The University of Texas MD Anderson Cancer Center
Jessica Maxwell
Assistant Professor
The University of Texas MD Anderson Cancer Center
Jin He
Professor
Johns Hopkins University School of Medicine
Humam Kadara
The University of Texas MD Anderson Cancer Center
Powel Brown
Professor and Chairman
The University of Texas MD Anderson Cancer Center
Christina Dieli-Conwright
Dana-Farber Cancer Institute
Manu Sebastian
PROFESSOR
The University of Texas MD Anderson Cancer Center
George Van Buren
Assistant Professor
Baylor College of Medicine
Guillermina Lozano
Professor and Chair
The University of Texas MD Anderson Cancer Center
Jay Kolls
Professor
Tulane University School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.